MRK Gains EU Approval for Keytruda/Padcev in Bladder Cancer; Franchise Extended but Core Thesis Unchanged

What happened

Merck secured EU approval for the Keytruda plus Padcev combination in resectable muscle-invasive bladder cancer for patients ineligible for cisplatin-based chemotherapy. While this label expansion adds a new indication to Keytruda, the addressable patient population is relatively small and does not meaningfully alter the drug's revenue trajectory. The approval is consistent with Merck's strategy of defending Keytruda's franchise through line extensions ahead of the 2028–2029 LOE, but it does not address the larger overhangs: the looming biosimilar/IRA pricing step-downs or the stalled Gardasil China recovery. At $119, the stock still prices in a 2026 holding pattern, with the next real catalysts being the April PDUFA date and Q2 commentary on the $2.5B headwind. The thesis remains unchanged: wait for evidence that Gardasil shipments resume and that the Keytruda erosion bridge holds before committing new capital.

Implication

Supports Keytruda's clinical utility but does not reduce concentration risk or alter the post-2028 transition math. Investors should focus on Gardasil China restart and the $2.5B 2026 headwind containment for a more material rerating.

Thesis delta

No shift. The EU approval for Keytruda/Padcev is a routine label expansion that does not change the WAIT thesis. The core uncertainties—Gardasil China restart timing and the Keytruda LOE path—remain unresolved. Management's ability to convert restructuring savings and recent BD into visible 2026–2027 revenue pillars still awaits proof.